An Observational Study of Predictors and Outcomes of Lung Cancer in Never-smokers in the UK
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- University College London Hospitals
- Enrollment
- 225
- Locations
- 1
- Primary Endpoint
- Demographics, comorbidities and environmental exposures of participants
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this observational study is to improve the early detection of lung cancer in adults who have smoked less than 100 tobacco cigarettes ("never-smokers") in the United Kingdom. The main questions it aims to answer are:
- To describe characteristics such as demographics, co-morbidities and environmental exposures
- To describe participant pathways including presentation mode and symptoms to understand if earlier diagnosis would be possible
- To describe participant outcomes such as cancer stage, treatment and mortality
- To quantitatively or qualitatively measure modifiable and non-modifiable factors that may be associated with LCINS including environmental measures, blood tests and genomic data.
Participants will currently have no change to their usual care.
Investigators
Neal Navani
Professor of Respiratory Medicine
University College, London
Eligibility Criteria
Inclusion Criteria
- •All adult participants from age of 18 who are diagnosed or treated with primary lung cancer through radiology or histology at any participating study site
Exclusion Criteria
- •Participants who have ever smoked cigarettes or tobacco will be excluded; this is defined as:
- •More than 100 cigarettes or 75g tobacco in their lifetime
- •Those who have received a prescription for nicotine replacement therapy
- •For prospective participants, those who cannot consent will be excluded
Outcomes
Primary Outcomes
Demographics, comorbidities and environmental exposures of participants
Time Frame: Comorbidities and environmental exposures at diagnosis (approximately up to 156 weeks prior to diagnosis)
From review of electronic health records
Participant pathways including presentation mode and symptoms
Time Frame: Presentation mode and symptoms at time of diagnosis (approximately up to 52 weeks prior to diagnosis)
From review of electronic health records
Secondary Outcomes
- Participant outcomes such as cancer stage, treatment, mortality(Cancer stage at time of diagnosis, treatment and mortality through study completion (likely 5 years))
- Measurement of modifiable and non-modifiable factors associated with LCINS(Through study completion (likely 5 years))